Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion

Stem Cells

Volumn 34, Issue 8, 2016, Pages 2026-2039

  Otvos, Balint ^a   Silver, Daniel J ^a   Mulkearns Hubert, Erin E ^a   Alvarado, Alvaro G ^a,b   Turaga, Soumya M ^a   Sorensen, Mia D ^e,f   Rayman, Patricia ^a   Flavahan, William A ^a,b   Hale, James S ^a   Stoltz, Kevin ^a   Sinyuk, Maksim ^a   Wu, Qiulian ^a   Jarrar, Awad ^a   Kim, Sung Hak ^c   Fox, Paul L ^a,b,d   Nakano, Ichiro ^c   Rich, Jeremy N ^a,b,d   Ransohoff, Richard M ^a,b   Finke, James ^a,b,d   Kristensen, Bjarne W ^e,f   Vogelbaum, Michael A ^a,b,d   Lathia, Justin D ^a,b,d   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c University of Alabama at Birmingham   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cancer stem cells; Glioblastoma; Immunotherapy; Macrophage migration inhibitory factor; MIF; Myeloid derived suppressor cells; Tumor immune suppression; Tumor microenvironment

Indexed keywords

ARGINASE 1; CHEMOKINE RECEPTOR CXCR2; FLUOROURACIL; MACROPHAGE MIGRATION INHIBITION FACTOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR SECRETION; COCULTURE; CYTOTOXIC T LYMPHOCYTE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; STEM CELL SELF-RENEWAL; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT;

EID: 84982845015     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2393     Document Type: Article

References (56)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–996.
2. Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Gene Dev 2007;21:2683–2710.
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492–507.
4. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423–1437.
5. Kohanbash G, McKaveney K, Sakaki M et al. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through Interleukin-4 receptor. Cancer Res 2013;73:6413–6423.
6. Gielen PR, Schulte BM, Kers-Rebel ED et al. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. J Neuropathol Exp Neurol 2015;74:390–400.
7. Platten M, Kretz A, Naumann U et al. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 2003;54:388–392.
8. Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T-Cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66:3294–3302.
9. Lewis CE. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605–612.
10. Pyonteck SM, Akkari L, Schuhmacher AJ et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013;19:1264–1272.
11. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821–5828.
12. Singh SK, Clarke ID, Hide T et al. Cancer stem cells in nervous system tumors. Oncogene 2004;23:7267–7273.
13. Ignatova TN, Kukekov VG, Laywell ED et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002;39:193–206.
14. Hemmati HD, Nakano I, Lazareff JA et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003;100:15178–15183.
15. Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011–7021.
16. Bao S, Wu Q, Mclendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756–760.
17. Liu G, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
18. Chen J, Li Y, Yu T-S et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2013;488:522–526.
19. Wei J, Barr J, Kong LY et al. Glioblastoma cancer-initiating cells inhibit T-Cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2010;9:67–78.
20. Sarkar S, Döring A, Zemp FJ et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat Neurosci 2013;17:46–55.
21. Zhou W, Ke SQ, Huang Z et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol 2015;17:170–182.
22. Silver DJ, Sinyuk M, Vogelbaum MA et al. The intersection of cancer, cancer stem cells, and the immune system: Therapeutic opportunities. Neuro Oncol 2016;18:153.
23. Kaufmann JK, Chiocca EA. Glioma virus therapies between bench and bedside. Neuro Oncol 2014;16:334–351.
24. Wainwright DA, Chang AL, Dey M et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014;20:5290–5301.
25. Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148–2157.
26. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010;59:1593–1600.
27. Ozao-Choy J, Ma G, Kao J et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514–2522.
28. Raychaudhuri B, Rayman P, Ireland J et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011;13:591–599.
29. Eyler CE, Wu Q, Yan K et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011;146:53–66.
30. Lathia JD, Gallagher J, Heddleston JM et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010;6:421–432.
31. Li Z, Bao S, Wu Q et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009;15:501–513.
32. Ausman JI, Shapiro WR, Rall DP. Studies on the chemotherapy of experimental brain tumors: Development of an experimental model. Cancer Res 1970;30:2394–2400.
33. Hitomi M, Deleyrolle LP, Mulkearns-Hubert EE et al. Differential connexin function enhances self- renewal in glioblastoma. Cell Rep 2015;11:1031–1042.
34. Lathia JD, Li M, Sinyuk M et al. High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep 2014;6:117–129.
35. Youn JI, Collazo M, Shalova IN et al. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 2012;91:167–181.
36. Hu Y, Smyth GK. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70–78.
37. Christensen K, Schrøder HD, Kristensen BW. CD133 + niches and single cells in glioblastoma have different phenotypes. J Neurooncol 2010;104:129–143.
38. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061–1068.
39. Eruslanov EB, Bhojnagarwala PS, Quatromoni JG et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest 2014;124:5466–5480.
40. Vincent J, Mignot G, Chalmin F et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010;70:3052–3061.
41. Wu A, Oh S, Wiesner SM et al. Persistence of CD133 + cells in human and mouse glioma cell lines: Detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cell Dev 2008;17:173–184.
42. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004;432:396–401.
43. PeNuelas S, Anido J, Prieto-SAnchez RM et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009;15:315–327.
44. Anido J, Sáez-Borderías A, Gonzàlez-Juncà A et al. TGF-beta receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell 2010;18:655–668.
45. Simpson KD, Templeton DJ, Cross JV. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol 2012;189:5533–5540.
46. Lippitz BE. Review Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol 2013;14:e218–e228.
47. Mittelbronn M, Platten M, Zeiner P et al. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol 2011;122:353–365.
48. Hussain F, Freissmuth M, Volkel D et al. Human anti-macrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells in vitro and in vivo. Mol Cancer Ther 2013;12:1223–1234.
49. Põlajeva J, Bergström T, Edqvist P-H et al. Glioma-derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT5-dependent manner. Mol Oncol 2014;8:50–58.
50. Katoh H, Wang D, Daikoku T et al. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013;24:631–644.
51. Zhai H, Heppner FL, Tsirka SE. Microglia/macrophages promote glioma progression. Glia 2010;59:472–485.
52. Zheng Y, Li X, Qian X et al. Secreted and O-GlcNAcylated MIF binds to the human EGF receptor and inhibits its activation. Nat Cell Biol 2015;17:1348–1355.
53. Schulz R, Marchenko ND, Holembowski L et al. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med 2012;209:275–289.
54. Yu P, Lee Y, Liu W et al. Intratumor depletion of CD4 + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779–791.
55. Yaddanapudi, K. et al. MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation. Cancer Immunology Research 2016;4:101–112.
56. Gupta, Y., Pasupuleti, V., Du, W. & Welford, S. M. Macrophage Migration Inhibitory Factor Secretion Is Induced by Ionizing Radiation and Oxidative Stress in Cancer Cells. PLoS ONE 2016;11:e0146482–11.